Poliomyelitis, commonly known as polio, is a highly contagious viral disease primarily affecting children under the age of five. The disease accounts for approximately 1 in every 200 infections leading to irreversible paralysis, with 5% to 10% of those paralyzed dying due to respiratory muscle paralysis. Despite advances in vaccination, there remains a significant unmet clinical need for better therapies, as current treatments mainly focus on managing symptoms rather than providing a cure. The growing emphasis on vaccine development and antiviral research is expected to drive substantial growth in the polio drug pipeline, offering new hope for more effective treatments in the future.
The Poliomyelitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into poliomyelitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for poliomyelitis. The poliomyelitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The poliomyelitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with poliomyelitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to poliomyelitis.
Poliomyelitis, or polio, is a highly infectious viral disease caused by the poliovirus, which primarily affects children under five. It spreads through contaminated water or food, and, in severe cases, leads to paralysis or death. The poliovirus attacks the nervous system, damaging motor neurons that control muscles.
Poliomyelitis treatment involves supportive care to alleviate symptoms. The primary prevention method is vaccination, with the inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) providing effective immunity against the virus.
A 2024 report on circulating vaccine-derived poliovirus (cVDPV) cases highlights key epidemiological trends in the ongoing fight against poliomyelitis. In 2023, 522 cases were confirmed, with 43% of them occurring in the Democratic Republic of the Congo. The decreasing number of cVDPV2 emergence groups, including 14 derived from the novel oral polio vaccine type 2 (nOPV2), reflects progress in controlling poliomyelitis transmission. However, the detection of cVDPV in the environment, notably in Nigeria and other countries, underscores the importance of continued poliomyelitis surveillance and the development of effective vaccines and treatments to mitigate future risks.
This section of the report covers the analysis of poliomyelitis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total poliomyelitis clinical trials.
The drug molecule categories covered under the poliomyelitis pipeline analysis include small molecules, monoclonal antibodies, gene therapy, biologics, and immunomodulators. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for poliomyelitis.
The EMR poliomyelitis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in poliomyelitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for P\poliomyelitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of poliomyelitis drug candidates.
Sinovac Biotech Co., Ltd. is sponsoring a Phase 4 clinical trial to assess the immunogenicity and safety of a booster dose of the Sabin strain inactivated poliovirus vaccine (sIPV) co-administered with MMR and HepA-I vaccines. The study will involve around 960 participants and is expected to be completed by March 2025, focusing on vaccine efficacy and safety.
The clinical study, sponsored by Serum Institute of India Pvt. Ltd., aims to assess the immunogenicity and safety of a hexavalent vaccine containing a reduced dose of inactivated polio vaccine (IPV) for poliomyelitis. The study is expected to be completed by May 2026 and will involve 1,557 healthy infants and toddlers, with a primary completion date set for August 2025.
A Phase 1/2 randomized, double-blind study sponsored by CanSino Biologics Inc. aims to evaluate the safety and immunogenicity of the virus-like particle poliomyelitis vaccine in infants and toddlers. Participants will receive varying doses of the investigational vaccine. The study, expected to be completed by December 2026, will involve an estimated 480 participants. Blood and mucosal samples will be analyzed for immunogenicity.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Poliomyelitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for poliomyelitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within poliomyelitis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share